Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas
Preprint
- 28 August 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose Cutaneous squamous cell carcinoma (cSCC) is the second cancer in white-skinned populations. Few data exist about cSCC epidemiology, even less on advanced cases (acSCC). Our objectives were to analyze acSCC patients, to describe their characteristics, management, and outcomes over time. Methods A monocentric retrospective study was conducted over 5 years, including all patients who started a systemic therapy for acSCC. Patient’s characteristics, cSCC management, response to therapy, and survival were recorded. Patients were stratified in 2 periods (1 and 2). A subgroup analysis was performed comparing patients who received immunotherapy (group 1) to those who didn’t (group 2). Results The study included 127 patients, number of patients increased by an average of 19.7% per year. Most patients were males (88/127), elderly (mean 81.6 years), with comorbidities, 27.6% were immunocompromised. Median overall survival (OS) was better in the period 2 (20 months) compared to the period 1 (10 months)(HR [95% CI] = 0.62 [0.39; 0.98] p = 0.04). The risk of progression increased with age and immunosuppression. Of the 64 patients who received second-line therapy, 38 had immunotherapy (group 1) and 26 received other therapies (group 2). Immunotherapy reduced mortality and progression by respectively 71% (p = 0.004) and 67% ( p = 0.002). Conclusions Patients with acSCC are very frail and elderly. OS but not PFS increased with time, with a 2-fold improvement between period 1 and period 2. Access to immunotherapy in majority in period 2 did reduce mortality. Immunosuppression and advanced age were associated with lower PFS.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathologyBritish Journal of Dermatology, 2016
- Measuring current and future cost of skin cancer in EnglandJournal of Public Health, 2013
- The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factorsJournal of Surgical Oncology, 2012
- A systematic review of worldwide incidence of nonmelanoma skin cancerBritish Journal of Dermatology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Non-melanoma skin cancer: what drives tumor development and progression?Carcinogenesis, 2005
- Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2001
- Measuring comorbidity in older cancer patientsEuropean Journal of Cancer, 2000
- Proportional Hazards Tests and Diagnostics Based on Weighted ResidualsBiometrika, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987